139 related articles for article (PubMed ID: 38629975)
21. Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study.
Elamin AFM; Grafton-Clarke C; Wen Chen K; Obafemi T; Luvai A; Katira R; Davis G
Postgrad Med J; 2019 Feb; 95(1120):61-66. PubMed ID: 30709868
[TBL] [Abstract][Full Text] [Related]
22. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
Colivicchi F; Massimo Gulizia M; Arca M; Luigi Temporelli P; Gonzini L; Venturelli V; Morici N; Indolfi C; Gabrielli D; De Luca L
Cardiovasc Ther; 2020; 2020():3856242. PubMed ID: 31969932
[TBL] [Abstract][Full Text] [Related]
23. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
24. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
Du H; Li X; Su N; Li L; Hao X; Gao H; Kwong JS; Vandvik PO; Yang X; Nemeth I; Mordi IR; Li Q; Zhang L; Rao L; Lang CC; Li J; Tian H; Li S
Heart; 2019 Aug; 105(15):1149-1159. PubMed ID: 30842207
[TBL] [Abstract][Full Text] [Related]
25. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
27. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
[TBL] [Abstract][Full Text] [Related]
28. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials.
Bai J; Gong LL; Li QF; Wang ZH
J Clin Lipidol; 2018; 12(2):277-291.e3. PubMed ID: 29428832
[TBL] [Abstract][Full Text] [Related]
30. In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Shi W; Xu Y; Zhou L; Wang W; Huang W; Zhou B
Medicine (Baltimore); 2024 Mar; 103(10):e37416. PubMed ID: 38457555
[TBL] [Abstract][Full Text] [Related]
31. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.
Levintow SN; Orroth KK; Breskin A; Park AS; Flores-Arredondo JH; Dluzniewski P; Navar AM; Sørensen HT; Brookhart MA
Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):383-392. PubMed ID: 34894377
[TBL] [Abstract][Full Text] [Related]
32. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
33. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium.
Snel M; Descamps OS
Acta Cardiol; 2024 May; 79(3):311-318. PubMed ID: 37767917
[No Abstract] [Full Text] [Related]
35. Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction.
Nakamura A; Kanazawa M; Kagaya Y; Kondo M; Sato K; Endo H; Nozaki E
J Cardiol; 2020 Oct; 76(4):395-401. PubMed ID: 32439340
[TBL] [Abstract][Full Text] [Related]
36. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
37. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.
Almontashiri NA; Vilmundarson RO; Ghasemzadeh N; Dandona S; Roberts R; Quyyumi AA; Chen HH; Stewart AF
PLoS One; 2014; 9(9):e106294. PubMed ID: 25180781
[TBL] [Abstract][Full Text] [Related]
38. The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction.
Kong X; He G; Quan X; Tan Z; Yan F; Chen X
Medicine (Baltimore); 2024 Mar; 103(12):e37637. PubMed ID: 38517999
[TBL] [Abstract][Full Text] [Related]
39. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Schwartz GG; Giugliano RP
Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
[TBL] [Abstract][Full Text] [Related]
40. Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan.
Lin PL; Wu YW; Lin CF; Yeh HI; Chang WT; Charng MJ; Huang PH; Lin CC; Lin TH; Lin WW; Hsieh IC; Kuo FY; Chen CP; Li YH
J Atheroscler Thromb; 2023 Sep; 30(9):1123-1131. PubMed ID: 36418110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
